EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Aldosterone synthase inhibitors for uncontrolled and resistant hypertension in CKD: an assessment from bench to bedside

Marieta P Theodorakopoulou iD, Fotini Iatridi iD, Manfred Hecking iD, Pantelis Sarafidis iD

Nephrology Dialysis Transplantation · 2026

DOI: 10.1093/ndt/gfag013 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Marieta P Theodorakopoulou und 3 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Nephrology, Hippokration Hospital, Aristotle University Thessaloniki, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Hypertension, Cytochrome P-450 CYP11B2, Renal Insufficiency, Chronic, Drug Resistance. Die Arbeit nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertension is highly prevalent in chronic kidney disease (CKD) and frequently remains uncontrolled despite high treatment rates; resistant hypertension occurs in up to 40% of CKD patients and markedly increases renal and cardiovascular risk. Aldosterone dysregulation plays a central role in this setting, contributing not only to sodium retention and volume expansion but also to inflammation, fibrosis and target-organ damage in the kidney, heart and vasculature. While spironolactone is recommended as the preferable fourth agent in resistant hypertension, its use in advanced CKD is limited by scarce data, and high rates of hyperkalemia and declining kidney function. Aldosterone synthase inhibitors (ASIs) are an emerging therapeutic class that directly suppress aldosterone production. Recent Phase 2 and 3 randomized controlled trials demonstrate that next-generation, selective ASIs produce clinically meaningful reductions in office and ambulatory blood pressure (BP) in patients with uncontrolled and resistant hypertension, with an acceptable safety profile. Early Phase 2 trials have also shown that ASIs are effective in lowering office BP levels in CKD with accompanying substantial reductions in albuminuria. This review examines the potential clinical benefits of aldosterone synthesis targeted therapy in the management of uncontrolled and resistant hypertension in CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionCytochrome P-450 CYP11B2Renal Insufficiency, ChronicDrug ResistanceAntihypertensive AgentsHumansMineralocorticoid Receptor Antagonists

Stichwörter der Autor:innen

CKDalbuminuriaaldosteronealdosterone synthase inhibitorshypertension

Substanzen

Cytochrome P-450 CYP11B2Antihypertensive AgentsMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • First Department of Nephrology, Hippokration Hospital, Aristotle University Thessaloniki, Thessaloniki, Greece.
  • Department of Internal Medicine III, Clinical Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Marieta P Theodorakopoulou, Fotini Iatridi, Manfred Hecking, Pantelis Sarafidis

Zitieren

APA

Theodorakopoulou, M. P., Iatridi, F., Hecking, M., & Sarafidis, P. (2026). Aldosterone synthase inhibitors for uncontrolled and resistant hypertension in CKD: an assessment from bench to bedside. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag013

Vancouver

Theodorakopoulou MP, Iatridi F, Hecking M, Sarafidis P. Aldosterone synthase inhibitors for uncontrolled and resistant hypertension in CKD: an assessment from bench to bedside. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag013

BibTeX
@article{Theodorakopoulou2026,
  author = {Theodorakopoulou, Marieta P and Iatridi, Fotini and Hecking, Manfred and Sarafidis, Pantelis},
  title = {Aldosterone synthase inhibitors for uncontrolled and resistant hypertension in CKD: an assessment from bench to bedside},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag013}
}
Kostenlos starten →